Literature DB >> 8005805

Reoxygenation and rehypoxiation in the SCCVII mouse tumor.

I H Kim1, J M Brown.   

Abstract

PURPOSE: To test the hypothesis that, following preferential killing of tumor hypoxic cells, the fraction of hypoxic cells in the tumor will reestablish itself to pretreatment levels (rehypoxiation) with the same kinetics as for reoxygenation. METHODS AND MATERIALS: Mouse squamous cell carcinoma VII (SCCVII) tumors were treated with a single dose of 10 Gy or a single dose of the bioreductive hypoxic cell cytotoxin, tirapazamine (SR 4233, 0.2 mmol/kg), which preferentially kills hypoxic cells within the tumor. Hypoxic fractions were determined by the paired survival curve technique using the in vivo-in vitro clonogenic assay 0-24 h after treatment.
RESULTS: Immediately after irradiation with 10 Gy, the hypoxic fraction of the tumors increased to 80% and rapidly returned to pretreatment levels 3-6 h later. Within 1 h of injecting tirapazamine, the hypoxic fraction fell to 0.57% (about 7% of pretreatment levels) and returned to pretreatment levels 3-5 h later.
CONCLUSION: The return to pretreatment levels of hypoxia among tumor cells surviving a single dose of radiation (reoxygenation) and of the hypoxic cell toxin tirapazamine (rehypoxiation) was rapid and occurred with similar kinetics for the two processes. These data support the hypothesis that reoxygenation and rehypoxiation are different manifestations of the same phenomenon and result from fluctuating tumor blood flow which creates acute hypoxia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005805     DOI: 10.1016/0360-3016(94)90444-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.

Authors:  M J Dorie; M S Kovacs; E C Gabalski; M Adam; Q T Le; D A Bloch; H A Pinto; D J Terris; J M Brown
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Authors:  Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

3.  Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.

Authors:  T Shibata; Y Shibamoto; K Sasai; N Oya; R Murata; T Takagi; M Hiraoka; M Takahashi; M Abe
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.

Authors:  Satish K Chitneni; Gerald T Bida; Hong Yuan; Gregory M Palmer; Michael P Hay; Thorsten Melcher; William R Wilson; Michael R Zalutsky; Mark W Dewhirst
Journal:  J Nucl Med       Date:  2013-06-05       Impact factor: 10.057

5.  Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy.

Authors:  Hirotada Fujii; Koh-Ichi Sakata; Yoshihiro Katsumata; Rikiya Sato; Makoto Kinouchi; Masanori Someya; Shin-Ichiro Masunaga; Masato Hareyama; Harold M Swartz; Hiroshi Hirata
Journal:  Radiother Oncol       Date:  2008-02-20       Impact factor: 6.280

6.  Assessment of the changes in 9L and C6 glioma pO2 by EPR oximetry as a prognostic indicator of differential response to radiotherapy.

Authors:  Huagang Hou; Sriram P Mupparaju; Jean P Lariviere; Sassan Hodge; Jiang Gui; Harold M Swartz; Nadeem Khan
Journal:  Radiat Res       Date:  2013-02-07       Impact factor: 2.841

7.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy.

Authors:  Rob A Cairns; Ioanna Papandreou; Patrick D Sutphin; Nicholas C Denko
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

8.  Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy.

Authors:  Huagang Hou; Jean P Lariviere; Eugene Demidenko; David Gladstone; Harold Swartz; Nadeem Khan
Journal:  Radiother Oncol       Date:  2008-11-14       Impact factor: 6.280

9.  Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.

Authors:  M S Kovacs; D J Hocking; J W Evans; B G Siim; B G Wouters; J M Brown
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

10.  Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.

Authors:  B G Siim; P L van Zijl; J M Brown
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.